Psychiatry Research
Volume 144, Issue 2 , Pages 177-189 , 15 November 2006

Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics

  • Frank D. Gianfrancesco

      Affiliations

    • HECON Associates, Inc., 9833 Whetstone Drive, Montgomery Village, MD 20886, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 301 963 5661; fax: +1 301 990 7641.
    • ,
  • Krithika Rajagopalan

      Affiliations

    • AstraZeneca, Wilmington, DE, United States
    • ,
  • Martha Sajatovic

      Affiliations

    • Case Western Reserve University School of Medicine, Department of Psychiatry and University Hospitals of Cleveland, United States
    • ,
  • Ruey-hua Wang

      Affiliations

    • HECON Associates, Inc., 9833 Whetstone Drive, Montgomery Village, MD 20886, United States

Received 29 August 2005 ,Revised 6 January 2006 ,Accepted 8 February 2006.

References 

  1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry. 1999;156:1686–1696
  2. Al-Zakwani IS, Barron JJ, Bullano MF, Arcona S, Drury CJ, Cockerham TR. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotics. Current Medical Research and Opinion. 2003;19:619–626
  3. Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. International Clinical Psychopharmacology. 1995;10(Suppl 3):123–132
  4. Bebbington PE. The content and context of compliance. International Clinical Psychopharmacology. 1995;9:41–50(Suppl)
  5. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica. 2000;106:286–290
  6. Corrigan PW, Reinke RR, Landsberger SA, Charate A, Toombs GA. The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophrenia Research. 2003;63:97–101
  7. Corriss DJ, Smith TE, Hull JW, Lim RW, Pratt SI, Romanelli S. Interactive risk factors for treatment adherence in a chronic psychotic disorders population. Psychiatry Research. 1999;89:269–274
  8. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents?. American Journal of Psychiatry. 2002;159:103–108
  9. Garcia-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez de Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry. 2001;1:7
  10. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Annals of Clinical Psychiatry. 2002;14:47–57
  11. Gilbert PL, Harris ML, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Archives of General Psychiatry. 1995;52:173–188
  12. Gilmer TP, Kolder CR, Lacro JP. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry. 2004;161:692–699
  13. Ginsberg DL, Schooler NR, Buckley PF, Harvey PD, Weiden PJ. Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning. CNS Spectrums. 2005;10:1–13
  14. Hamilton RA, Briceland LL. Use of prescription-refill records to assess patient compliance. American Journal of Hospital Pharmacy. 1992;49:1691–1696
  15. Heysue BE, Levin GM, Merrick JP. Compliance with depot medication by patients attending outpatient clinics. Psychiatric Services. 1998;49:1232–1234
  16. ICD-9-CM Code Book, 1998. St. Anthony Publishing, Salt Lake City, UT.
  17. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. International Journal of Neuropsychopharmacology. 2003;6:325–337
  18. Kelly GR, Mamon JA, Scott HE. Utility of the health belief model in examining medication compliance among psychiatric outpatients. Social Science & Medicine. 1990;25:1205–1211
  19. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication non-adherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry. 2002;63:892–909
  20. Lehman AF, Steinwachs DM Survey Co-investigators of the PORT project. Translation research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin. 1998;24:1–10
  21. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry. 2003;160:1396–1404
  22. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine. 2005;353:1209–1223
  23. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. European Neuropsychopharmacology. 2001;11:25–32
  24. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatric Services. 2003;54:719–723
  25. Nagoette C, Sullivan G, Duan N, Camp PL. Medication compliance among the seriously mentally ill in a public health system. Social Psychiatry and Psychiatric Epidemiology. 1997;32:49–56
  26. Nasrallah HA, Mulvihill T. Iatrogenic disorders associated with conventional vs. atypical antipsychotics. Annals of Clinical Psychiatry. 2002;13:215–217
  27. Norquist GS, Regier DA. The epidemiology of psychiatric disorders and the de facto mental health care system. Annual Review of Medicine. 1996;47:473–479
  28. Nose M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychological Medicine. 2003;33:1149–1160
  29. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services. 2000;51:216–222
  30. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatric Services. 1996;47:853–858
  31. Pan PC, Tantam D. Clinical characteristics, health beliefs, and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic. Acta Psychiatrica Scandinavica. 1989;79:564–570
  32. Perkins DO. Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry. 2002;63:1121–1128
  33. Rittmannsberger H, Pachinger T, Keppelmuller PO, Wancata J. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatric Services. 2004;44:174–179
  34. Robinson DG, Woerner MG, Alvir JM. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research. 2002;57:209–219
  35. Rosenhack R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. Journal of Clinical Psychiatry. 2000;61:382–386
  36. Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio RV. Treatment adherence with atypical antipsychotics among patients with bipolar disorder. In: Poster presented at the Sixth International Conference on Bipolar Disorder, Pittsburgh, PA, June 16–18. 2005;
  37. Smith S. Effects of antipsychotics on sexual and endocrine functions in women: implications for clinical practice. Journal of Clinical Psychopharmacology. 2003;23:S27–S32
  38. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services. 2001;52:805–811
  39. Third Annual National Psychosis Registry Report . Care for Veterans with Psychosis in the VHA. 2001;Available at: www.hsrd.ann-arbor.med.va.gov. Last accessed May 17, 2005
  40. Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors?. International Journal of Neuroscience. 2004;114:593–611
  41. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care. 2002;40:630–639
  42. Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin. 2004;30:255–264
  43. Van Putten T. Why do schizophrenic patients refuse to take their drugs?. Archives of General Psychiatry. 1974;31:67–72
  44. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research. 2004;66:51–57
  45. Yen YC, Lung FW, Chong MY. Adverse effects of risperidone and haloperidol treatment in schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2004;28:285–290
  46. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bulletin of the American Academy of Psychiatry and the Law. 1986;14:105–122

PII: S0165-1781(06)00031-X

doi: 10.1016/j.psychres.2006.02.006

Psychiatry Research
Volume 144, Issue 2 , Pages 177-189 , 15 November 2006

Article Tools

* Image Usage & Resolution